The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.

Five Vanderbilt University Medical Center hematology and oncology fellows will receive awards from Conquer Cancer, the ASCO Foundation, during the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, June 3-7.

Without the lung transplant, the cancer may never have been detected.

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Vanderbilt's Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.